Trials / Completed
CompletedNCT04340193
A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer
A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of nivolumab with and without ipilimumab in combination with Trans-arterial ChemoEmbolization (TACE) to TACE alone in participants with intermediate liver cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nivolumab | Specified dose on specified days |
| DRUG | ipilimumab | Specified dose on specified days |
| PROCEDURE | TACE | TACE (Trans-arterial ChemoEmbolization) |
Timeline
- Start date
- 2020-09-14
- Primary completion
- 2023-12-12
- Completion
- 2023-12-12
- First posted
- 2020-04-09
- Last updated
- 2024-11-26
- Results posted
- 2024-11-26
Locations
107 sites across 19 countries: United States, Australia, Austria, Belgium, Canada, China, Czechia, France, Germany, Hong Kong, Italy, Japan, Poland, Puerto Rico, Russia, Singapore, South Korea, Spain, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04340193. Inclusion in this directory is not an endorsement.